Drug
Omega-3 (EPA+DHA)
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)
Phase Distribution
Ph phase_1
1
50%
Ph phase_2
1
50%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Terminated(1)
Detailed Status
Terminated1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (50.0%)
Phase 21 (50.0%)
Trials by Status
terminated150%
not_yet_recruiting150%
Recent Activity
0 active trials
Showing 2 of 2
not_yet_recruitingphase_2
Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial
NCT07118059
terminatedphase_1
Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers
NCT05121766
Clinical Trials (2)
Showing 2 of 2 trials
NCT07118059Phase 2
Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial
NCT05121766Phase 1
Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2